Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Women's Cancer Study Group GmbH
With
Teva Pharmaceuticals USA
Age
70–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female patients, age at diagnosis 18 years and above (consider patients at 70 years and above for ADAPT Elderly)
Candidate for chemotherapy on the basis of conventional criteria
Histologically confirmed unilateral primary invasive carcinoma of the breast
Clinical T1 - T4a-c
All clinical N (cN)
No clinical evidence for distant metastasis (M0)
Known HR status and HER2 status (local pathology)
Tumor block available for central pathology review
Performance Status ECOG \<= 1 or KI \>= 80%
Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements
The patient must be accessible for treatment and follow-up
Patients must qualify for neoadjuvant treatment
LVEF \> 50%; LVEF within normal limits of each institution measured by echocardiography and normal ECG (within 42 days prior to chemotherapy)
* Laboratory requirements :
* Leucocytes ≥ 3.5 x 109/L
* Platelets ≥ 100 x 109/L
* Hemoglobin ≥ 10 g/dL
* Total bilirubin ≤ 1 x ULN
* ASAT (SGOT) and ALAT (SGPT) ≤ 2.5 x UNL
* Creatinine ≤ 175 µmol/L (2 mg/dl)
≥ 70 years old
Charlson scale ≤ 2
HR+/HER2- disease: if RS and sequential testing are available N0-1/RS 12-25/poor response or N0-1/RS ≥26
All G3 with Ki-67 ≥40% in tumors \>1cm
All N2
All TN
All subtypes
You may not be if
Known hypersensitivity reaction to the compounds or incorporated substances
Prior malignancy with a disease-free survival of \< 10 years, except curatively treated basalioma of the skin, pTis of the cervix uteri
Non-operable breast cancer including inflammatory breast cancer
Previous or concurrent treatment with cytotoxic agents for any reason after consultation with the sponsor
Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry (concurrent participation in non-interventional post authorization safety studies not influencing the primary study endpoints is allowed, e.g. WSG PROTROCA for evaluation of primary/secondary G-CSF prophylaxis)
Male breast cancer
Sequential breast cancer
Reasons indicating risk of poor compliance
Patient not able to consent
Known polyneuropathy ≥ grade 2
Severe and relevant co-morbidity that would interact with the application of cytotoxic agents or the participation in the study
Inadequate organ function (e.g. hepatic impairment, pulmonary disease, etc.)
Uncompensated cardiac function (current unstable ventricular arrhythmia requiring treatment, history of symptomatic CHF NYHA classes II-IV), history of myocardial infarction or unstable angina pectoris within 12 months of enrollment, history of severe hypertension, CAD - coronary artery disease)
Severe dyspnea
Pneumonitis
Abnormal blood values:
Thrombocytopenia \> CTCAE grade 1
Increases in ALT/AST \> CTCAE grade 1
Hypokalaemia \> CTCAE grade 1
Neutropenia \> CTCAE grade 1
Anaemia \> CTCAE grade 1
Clareo Health | A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response
